# GE HealthCare Technologies Inc. (GEHC)

> Source: Nexqual · https://nexqual.com/GEHC · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, GE HealthCare Technologies Inc. (GEHC), nexqual.com/GEHC" · informational, not investment advice.

**Price:** USD 71.42 (+3.49% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 69.01 · day 69.31–71.7 · 52w 58.75–89.77 · market cap $32.3B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $21.3B, net income $1.99B (9.3% margin), free cash flow $1.58B (SEC filings).
- Valuation: P/E 16.3x (avg 19.5x at the last 3 fiscal year-ends), EV/EBITDA 13.3x, net debt $8.01B.
- 8 of 80 tracked superinvestors hold GEHC (13F, Q2 2026): 2 new, 3 added, 2 reduced, 1 unchanged.
- Insider open-market purchases, last ~7 months: 8 Form 4 filings, $6.4M; 0 by opportunistic insiders, 0 by routine insiders.
- Total return with dividends: 1Y -7.4% vs S&P 500 +14.9%; 5Y +26.6% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD 1.2, revenue estimate $5.35B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $17.6B | $18.3B | $19.6B | $19.7B | $20.6B | $21.3B |
| Gross profit | $7.17B | $7.18B | $7.92B | $8.21B | $8.25B | — |
| Operating income | $2.79B | $2.52B | $2.44B | $2.63B | $2.76B | $2.73B |
| Net income | $2.25B | $1.92B | $1.57B | $1.99B | $2.08B | $1.99B |
| EPS (diluted) | $4.95 | $4.22 | $3.03 | $4.34 | $4.55 | — |
| Free cash flow | $1.36B | $1.82B | $1.71B | $1.55B | $1.50B | $1.58B |
| Gross margin | 40.8% | 39.1% | 40.5% | 41.7% | 40.0% | — |
| Operating margin | 15.9% | 13.8% | 12.5% | 13.3% | 13.4% | 12.9% |
| Net margin | 12.8% | 10.4% | 8.0% | 10.1% | 10.1% | 9.3% |
| Revenue growth | — | +4.3% | +6.6% | +0.6% | +4.8% | — |
| Cash + short-term investments | $561M | $1.44B | $2.49B | $2.87B | $4.49B | — |
| Total debt | — | $8.25B | $9.44B | $8.95B | $10.0B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 16.3x · P/S 1.5x · EV/EBITDA 13.3x · EV/Sales 1.9x · P/FCF 20.4x · P/B 2.9x · FCF yield 4.89% · Earnings yield 6.15% · Dividend yield (paid, TTM) 0.20% · Buyback yield (TTM) 1.24% · Net debt $8.01B · EV $40.3B
P/E at fiscal year-ends: Dec 2025 18.0x, Dec 2024 18.0x, Dec 2023 22.6x.

## Superinvestors (SEC 13F-HR, Q2 2026)
8 of 80 tracked investors hold GEHC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Nelson Peltz | Trian Fund Management | 4.67% | $197M | New position |
| Leon Cooperman | Omega Family Office | 2.36% | $83.8M | Added +95.5% |
| Harry Burn | Sound Shore | 2.21% | $71.6M | Reduced -6.2% |
| Bill Nygren | Oakmark Funds | 1.31% | $981M | Reduced -1.7% |
| Dodge & Cox Funds | Dodge & Cox | 1.27% | $2.42B | Added +20.9% |
| First Pacific Advisors |  | 0.66% | $53.0M | New position |
| Christopher Bloomstran | Semper Augustus | 0.03% | $293K | Unchanged |
| First Eagle Investment | First Eagle Investment Management | <0.01% | $16K | Added +347.3% |

## Insider purchases (SEC Form 4, open-market, last ~7 months)
8 purchases, $6.4M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-05-22 | Lobo Kevin | Director | 10,000 | $642K | 64.18 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-12 | Hochman Rodney F | Director | 1,618 | $100K | 62.03 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-08 | Yang Watkin Phoebe L. | Director | 1,000 | $63K | 63.01 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-06 | Culp H Lawrence Jr | Director | 80,805 | $5.0M | 61.88 | Too little history (no open-market trades in 2024 or 2025) |
| 2026-05-06 | Stromberg William J | Director | 1,000 | $62K | 61.69 | Too little history (no open-market trades in 2023–2025) |
| 2026-05-01 | Saccaro James | Chief Financial Officer | 3,310 | $201K | 60.6 | Too little history (no open-market trades in 2023–2025) |
| 2026-04-30 | Jimenez Frank R | GC & Corporate Secretary | 1,750 | $106K | 60.45 | Too little history (no open-market trades in 2023 or 2025) |
| 2026-04-30 | Arduini Peter J | President and CEO | 4,169 | $250K | 59.92 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | BTIG | Target lowered | Buy | $79 → $75 |
| 2026-10-07 | Barclays | Initiated | Overweight | $85 |
| 2026-10-05 | Citigroup | Target lowered | Neutral | $75 → $71 |
| 2026-10-05 | Needham | Reiterated | Buy | $93 |
| 2026-09-22 | Needham | Initiated | Buy | $93 |
| 2026-09-17 | BTIG | Reiterated | Buy | $79 |
| 2026-08-19 | BTIG | Reiterated | Buy | $79 |
| 2026-07-31 | UBS | Target raised | Neutral | $67 → $73 |
| 2026-07-30 | Citigroup | Target raised | Neutral | $69 → $75 |
| 2026-07-30 | Evercore ISI Group | Target raised | Outperform | $80 → $84 |
| 2026-07-30 | Wells Fargo | Target raised | Overweight | $75 → $85 |
| 2026-07-29 | BTIG | Target raised | Buy | $75 → $79 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2022-12-12) |
|---|---|---|
| Total return | -7.4% | +26.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -7.4% | +6.3% |
| Volatility (annualized) | 34.9% | 32.0% |
| Max drawdown | -32.5% (Jan 2026→Apr 2026) | -35.4% (Mar 2024→Mar 2025) |

## Peers (Medical Devices)
DXCM (DexCom, Inc.) USD 78.32 -2.42% · PHG (Koninklijke Philips N.V. NY Reg) USD 26.92 +2.63% · STE (STERIS plc (Ireland)) USD 232.22 +4.85% · EW (Edwards Lifesciences Corporatio) USD 90.09 +1.91% · ZBH (Zimmer Biomet Holdings, Inc.) USD 98.81 +4.16% · BSX (Boston Scientific Corporation) USD 46.01 +3.37%

## More
Full page: https://nexqual.com/GEHC · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in GEHC's own 10-K filed 2026-02-04 (https://www.sec.gov/Archives/edgar/data/1932393/000193239326000007/gehc-20251231.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Competitor | Siemens | "In the industries we serve, we believe our primary global competitors include Siemens Healthineers, Philips Healthcare, United Imaging, Mindray, and Canon, among others." |

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| AIS | $3.77B | 71.2% | +8.0% |
| PDx | $843.0M | 15.9% | +15.6% |
| PCS | $675.0M | 12.7% | -13.2% |
| Total revenue | $5.29B | 100% | — |

## Revenue by product line (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Product | $3.42B | 64.5% | +4.7% |
| Service | $1.88B | 35.5% | +7.7% |
| Total revenue | $5.29B | 100% | — |

## Revenue by region (fiscal year ended 2025-12-31)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Other Countries | $9.43B | 45.7% | +5.7% |
| UNITED STATES | $9.17B | 44.5% | +6.4% |
| China | $2.03B | 9.8% | -4.9% |
| Total revenue | $20.63B | 100% | — |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $1.20 | $1.24 | -3.2% | $5.35B | 18 |
| Next quarter (ends 2026-12-31) | $1.59 | $1.61 | -1.5% | $5.94B | 16 |
| Current fiscal year (ends 2026-12-31) | $4.92 | $4.87 | +1.1% | $21.72B | 22 |
| Next fiscal year (ends 2027-12-31) | $5.41 | $5.36 | +0.9% | $22.73B | 22 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-10-30 (includes earnings 2026-10-28): ±7.1%; last 8 reports averaged ±6%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-10-30 | 7 | 59.9% | ±7.1% |
| 2026-11-06 | 14 | 47.9% | ±7.7% |
| 2026-11-13 | 21 | 38.5% | ±7.5% |
| 2026-11-20 | 28 | 37.1% | ±8.3% |
| 2026-11-27 | 35 | 34.3% | ±8.6% |
| 2026-12-04 | 42 | 35.2% | ±9.6% |
| 2026-12-18 | 56 | 40.1% | ±12.7% |
| 2027-01-15 | 84 | 32.8% | ±12.7% |